Incyte

News

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

News

Joy as NICE changes tack on first NHS vitiligo treatment

NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.

News

Incyte's PD-1 drug brings immunotherapy to anal cancer

Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer

News

Sun Pharma overturns block on alopecia drug launch in US

Sun Pharma successfully removed an injunction on the launch of its Leqselvi for alopecia areata, a common form of hair loss, in the US.

News

Incyte blocks US launch of Sun Pharma's alopecia drug

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

News

ESMO: Incyte's PD-1 treads new ground in anal cancer

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programm

Incyte breaks new ground in anal cancer with EU approval

Joy as NICE changes tack on first NHS vitiligo treatment

Incyte's PD-1 drug brings immunotherapy to anal cancer

Sun Pharma overturns block on alopecia drug launch in US

Incyte blocks US launch of Sun Pharma's alopecia drug

ESMO: Incyte's PD-1 treads new ground in anal cancer

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Using AI-driven synthetic personas to take your insights fur...

Incyte

Editor's Picks